IP Library › Granted Patent US 10,441,571
Granted Patent B2
US 10,441,571 · App. 15/969,186 · Granted Oct 15, 2019

Spiro-lactam NMDA receptor modulators and uses thereof

Inventors: John A. Lowe, III (Stonington, CT); M. Amin Khan (Evanston, IL)
Assignee: Aptinyx Inc.
A61K31/407A61K31/397C07D487/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,441,571
App. No.
15/969,186
Granted
Oct 15, 2019
Kind
B2
Abstract

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Claims (6)

1. A compound represented by:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition, the pharmaceutical composition comprising:

a compound represented by:

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable excipient.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2023
From: APTINYX INC.
To: TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED
Reel/Frame 065426/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2018
From: LOWE, JOHN A., III; KHAN, M. AMIN
To: NAUREX, INC.
Reel/Frame 045714/0372 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2018
From: NAUREX, INC.
To: APTINYX INC.
Reel/Frame 045714/0379 →
Continuity (4)
Continuation 15337605 · Oct 28, 2016
Continuation 14764395
Provisional Application 61757903 · Jan 29, 2013
Related Publication 20180250267A1 · Sep 6, 2018